Variant: rs121913254 

    present in Gene: NRAS
    present in Chromosome: 1
    Position on Chromosome: 114713909
    Alleles of this Variant: G/A;C;T

rs121913254 in NRAS gene and GIANT PIGMENTED HAIRY NEVUS PMID 18633438 2009 Genotypic and gene expression studies in congenital melanocytic nevi: insight into initial steps of melanotumorigenesis.

PMID 23392294 2013 Multiple congenital melanocytic nevi and neurocutaneous melanosis are caused by postzygotic mutations in codon 61 of NRAS.

rs121913254 in NRAS gene and Neurocutaneous melanosis PMID 23392294 2013 Multiple congenital melanocytic nevi and neurocutaneous melanosis are caused by postzygotic mutations in codon 61 of NRAS.

rs121913254 in NRAS gene and melanoma PMID 23614898 2013 Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors.

PMID 25157968 2014 Prospective enterprise-level molecular genotyping of a cohort of cancer patients.

PMID 20179705 2010 RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF.

PMID 16291983 2005 Distinct sets of genetic alterations in melanoma.

PMID 18390968 2008 Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers.

PMID 2674680 1989 N-ras mutations in human cutaneous melanoma from sun-exposed body sites.

PMID 22761467 2012 First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors.

PMID 23414587 2013 MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study.

PMID 23076151 2012 We generated mutant BRAF(V600E) melanoma cells that exhibit resistance to PLX4720, the tool compound for vemurafenib, that co-expressed mutant (Q61K) NRAS.

PMID 20130576 2010 RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.

PMID 23538902 2013 Inhibition of Wee1, AKT, and CDK4 underlies the efficacy of the HSP90 inhibitor XL888 in an in vivo model of NRAS-mutant melanoma.

PMID 8120410 1994 Ras mutations in human melanoma: a marker of malignant progression.

PMID 23569304 2013 Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma.